Bobby Gaspar is a physician/scientist working in paediatric immunology at the Institute of Child Health (ICH) and Great Ormond Street London, as well as co-founder and chief Executive Officer at Orchard Therapeutics, a biotechnology company arising from his work at UCL/GOSH that is making gene therapy medicines for severe genetic diseases. He initially trained in paediatrics and then became interested in primary immunodeficiencies. His interests are in many different aspects of primary immunodeficiency including understanding the molecular and cellular defects and disease pathogenesis, bone marrow transplantation for severe immunodeficiencies and the development of gene and cell therapy for these conditions. Over the last decade, his team have conducted clinical trials that have shown that their approach to gene therapy can potentially permanently correct the immune defect in specific immunodeficiency conditions.